New York & Pittsburgh – November 21, 2016 – RenovaCare, Inc., (RCAR), developer of the patented CellMist™ and SkinGun™ technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of Roger Esteban-Vives, Ph.D. as Director of Cell Sciences.
“I’m thrilled to be joining the RenovaCare team to help bring to market the company’s breakthrough stem cell spray technology, the SkinGun™,” said Dr. Roger Esteban-Vives. “What makes the SkinGun™ unique is its ability to gently spray large areas of wounds and burns with a patient’s own stem cells, within only minutes of arriving in an emergency ward. Best of all, the process is entirely natural, quick and gentle.”
Watch video: Remarkable ‘before-after’ patient recovery using RenovaCare SkinGun™.
RenovaCare is developing its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare believes the technology will be a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the U.S. alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics. Dr. Roger Esteban-Vives, Director, Cell Sciences, RenovaCare, Inc.
Key to the RenovaCare approach is its ultra-gentle delivery of regenerative stem cells to the wound site. The company’s SkinGun™ achieves uniform distribution of fluids with 200 times greater coverage than conventional methods, according to tests conducted at Stem cell Systems GmbH (Berlin, Germany).
In addition to laboratory tests showing high distribution and concentration patterns, the SkinGun™ has also demonstrated its ability to spray powerful yet delicate skin stem cells ultra- gently, without damaging the cells. Cell viability is essential to regenerating skin for burns, wounds, and cosmetic applications.
SkinGun™ achieved impressive 97.3% cell viability after spraying, according to studies conducted by scientists at one of the world’s largest university hospitals, Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité – Universitätsmedizin Berlin.
“We’ve achieved some impressive technical results to-date. The next steps for us are to advance our breakthrough technology towards market through the regulatory and clinical studies process,” said Thomas Bold, President and CEO of RenovaCare, Inc. “I especially welcome the addition of Dr. Esteban-Vives to our team. He is one of the few scientists in the world with such deep experience in the isolation and spray of human stem cells, and we’re fortunate to have him join us.”
Among the world’s leading experts in the isolation of specific stem cells that are ideal for spraying onto burns and wounds, his research includes epidermal-dermal isolation of stem cells and investigations of post-spray dressings and their effect on freshly isolated keratinocytes.
Previously, at the McGowan Institute of Regenerative Medicine (University of Pittsburgh), Dr. Esteban-Vives worked extensively with skin stem cells, their spray application to burns, and investigation of the impact that commercially-available wound dressings have on such cells.
Dr. Esteban-Vives received his bachelor in molecular biology at the University Autonoma of Barcelona (Barcelona, Spain). He worked as a molecular biologist from 2001 through 2003 at IRTA in Cabrils, Spain.
In 2003 he joined the pharmaceutical company, Oryzon Genomics in Barcelona, Spain, and was instrumental in developing a new technology to induce and detect mutations in organisms via high-throughput molecular detection systems. From this work, he received his Ph.D. in biotechnology from the University of Barcelona.
Dr. Esteban-Vives is published in various scientific journals and lectures at national and international scientific conferences around the world. He is also an Editorial Board Member of the Journal of Acute Disease, and serves as a scientific reviewer for a myriad of scientific journals.
